Aprogen Biologics Inc, formerly Aprogen Pharmaceuticals Inc, is a Korea-based company principally engaged in the pharmaceutical business. The Company operates its business through two segments. The Medicine Business segment is engaged in the manufacture and sale of central nervous system drugs, autonomic agents, arteriosclerosis agents, metabolic agents, circulatory system drugs, biopharmaceuticals and others. The Segment is also engaged in the manufacture and sale of cosmetics such as skin moisturizers and others. The Gaming Business segment is engaged in the development and operation of role-playing games (RPGs).

Employees

391

Sector

Pharmaceuticals

Calendar

Mar. 11 - Q4 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
26-02-10	454.00 ₩	-3.40%	4,455,930
26-02-09	470.00 ₩	-1.05%	2,272,442
26-02-06	475.00 ₩	-2.06%	586,504
26-02-05	485.00 ₩	-1.02%	1,068,981
26-02-04	490.00 ₩	-5.95%	2,120,735

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Korea S.E. Other stock markets 2026-02-10			5-day change	1st Jan Change
454.00 ^KRW	-3.40%		-12.86%	-12.52%

Nov. 13	Aprogen Biologics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-10-23	Aprogen Biologics Inc. announced that it has received KRW 15 billion in funding from APTN Inc.	CI

Capitalization	103B 70.45M 59.2M 53.98M 51.54M 95.37M 6.38B 99.63M 627M 250M 3.07B 264M 259M 10.86B	P/E ratio 2023	-1.55x	P/E ratio 2024	-0.79x
Enterprise value	218B 150M 126M 115M 110M 203M 13.58B 212M 1.33B 531M 6.54B 562M 551M 23.12B	EV / Sales 2023	4.14x	EV / Sales 2024	3.66x
Free-Float	23.46%	Yield 2023 *	-	Yield 2024	-

Nov. 13	Aprogen Biologics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-10-23	Aprogen Biologics Inc. announced that it has received KRW 15 billion in funding from APTN Inc.	CI
25-10-15	Aprogen Biologics Inc. announced that it expects to receive KRW 15 billion in funding from APTN Inc.	CI
25-08-13	Aprogen Biologics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-05-21	Aprogen Medicines Inc. agreed to acquire an additional 20.06% stake in AP Healthcare Inc. from Aprogen Biologics Inc. for KRW 58.4 billion.	CI
25-05-14	Aprogen Biologics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-03-26	Aprogen Biologics Inc. announced that it has received KRW 65 billion in funding from APT Neuroscience, Inc.	CI
25-03-25	Aprogen Biologics Inc. announced that it expects to receive KRW 65 billion in funding from APT Neuroscience, Inc.	CI
25-03-14	Aprogen Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
24-11-13	Aprogen Biologics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
24-08-14	Aprogen Biologics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
24-07-31	Aprogen Biologics Inc. announced that it has received KRW 70.000000384 billion in funding from Aprogen Medicines Inc.	CI
24-07-22	An undisclosed buyer agreed to acquire 6.87% stake in Aprogen Biologics Inc. from Aprogen Medicines Inc. for KRW 43.9 billion.	CI

20-11-23	MÄRKTE ASIEN/Kräftige Gewinne in Seoul und Schanghai - Tokio pausiert
20-11-23	MÄRKTE ASIEN/Aufwärts mit Impfstoff-Optimismus

Aprogen Biologics Inc. Stock

Equities

A003060

KR7003060001

Pharmaceuticals

Valuation: Aprogen Biologics Inc.

Chart: Aprogen Biologics Inc.

Latest news: Aprogen Biologics Inc.

News in other languages: Aprogen Biologics Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Aprogen Biologics Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	-3.40%
1 week	-12.86%
Current month	-15.93%
1 month	-11.84%
3 months	-20.49%
6 months	-27.24%
Current year	-12.52%

Manager	Title	Age	Since
Jung-Chool Kim CEO	Chief Executive Officer	69	2012-03-31
Jae-Seob Kim CEO	Chief Executive Officer	63	2023-10-12
Jong-Soo Kang SAM	Sales & Marketing	62	-

Director	Title	Age	Since
Jung-Chool Kim BRD	Director/Board Member	69	2012-03-31
Dong-Chul Shin BRD	Director/Board Member	65	2020-03-22
Jae-Seob Kim BRD	Director/Board Member	63	2023-10-12

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
APROGEN BIOLOGICS INC.	-3.40%	-12.86%	-33.24%	-88.12%	61.63M
ELI LILLY AND COMPANY	-1.88%	+2.15%	+17.97%	+197.00%	918B
JOHNSON & JOHNSON	-0.12%	+2.25%	+54.53%	+46.99%	574B
ABBVIE INC.	-0.37%	-1.43%	+16.86%	+46.29%	393B
ROCHE HOLDING AG	-0.57%	-3.22%	+21.10%	+25.00%	366B
NOVARTIS AG	+0.40%	+2.04%	+23.54%	+50.61%	301B
ASTRAZENECA PLC	+0.35%	+2.30%	+21.41%	+23.56%	300B
MERCK & CO., INC.	-0.42%	+1.13%	+35.59%	+7.90%	291B
NOVO NORDISK A/S	-1.78%	+1.69%	-48.38%	-37.67%	223B
AMGEN INC.	-2.97%	+7.70%	+23.70%	+50.37%	196B
Average	-1.09%	-0.05%	+13.31%	+32.19%	356.28B
Weighted average by Cap.	-0.86%	+1.25%	+22.42%	+73.33%

	2023	2024
Net sales	87.36B 60.02M 50.44M 45.99M 43.91M 81.26M 5.44B 84.89M 534M 213M 2.62B 225M 220M 9.26B	67.38B 46.29M 38.9M 35.47M 33.87M 62.67M 4.19B 65.47M 412M 164M 2.02B 174M 170M 7.14B
Net income	-118B -81.26M -68.28M -62.25M -59.45M -110M -7.36B -115M -723M -288M -3.55B -305M -298M -12.53B	-105B -72.13M -60.61M -55.26M -52.77M -97.64M -6.53B -102M -642M -256M -3.15B -271M -265M -11.12B
Net Debt	171B 117M 98.69M 89.98M 85.92M 159M 10.64B 166M 1.04B 416M 5.12B 441M 431M 18.11B	116B 79.49M 66.8M 60.9M 58.16M 108M 7.2B 112M 707M 282M 3.47B 298M 292M 12.26B

1 week	433	493
1 month	433	566
Current year	433	566
1 year	433	887
3 years	433	7,240
5 years	433	14,000
10 years	433	82,600